Patents for A61P 35 - Antineoplastic agents (221,099)
09/2004
09/22/2004CN1167420C Azabanzimidazole-based compounds for modulating serine/threonine protein kinase function
09/22/2004CN1167417C Use of curcumin and its derivatives in preparing medicine for chronic granulocytic leukemia
09/21/2004US6795776 Crystallographic structure of the androgen receptor ligand binding domain
09/21/2004US6794545 Conformationally restricted polyamine analogs as disease therapies
09/21/2004US6794541 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
09/21/2004US6794523 Anticancer agents, antitumor agents; leukemia
09/21/2004US6794516 Synthesis of clasto-lactacystin β-lactone and analogs thereof
09/21/2004US6794512 Antiinflammatory agents; cyclooxygenase inhbitors; anticancer agents; autoimmune disease
09/21/2004US6794507 Compounds that inhibit factor Xa activity
09/21/2004US6794494 Can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells; for diagnosis and therapy of primary tumors
09/21/2004US6794416 Treatment of chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in humans that smoke or smoked cigarettes using aerosol or nebulizing device with or without concommitant treatment
09/21/2004US6794406 For therapy and prophylaxis of arteriosclerosis and hypercholesterolaemia
09/21/2004US6794403 Substituted benzoxazoles as estrogenic agents
09/21/2004US6794398 Preventive/remedies for liver diseases
09/21/2004US6794397 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
09/21/2004US6794395 Substituted indolinones, their manufacture and their use as medicaments
09/21/2004US6794384 Hydroxylation activated drug release
09/21/2004US6794382 Benzimidazole derivatives, preparation and therapeutic use thereof
09/21/2004US6794370 Method for treating cancer using camptothecin derivatives and 5-fluorouracil
09/21/2004US6794364 Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
09/21/2004US6794363 Isolated amyloid inhibitor protein (APIP) and compositions thereof
09/21/2004US6794178 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders
09/21/2004US6794169 Enzymatic polypeptide for use in the biosynthesis of glycans
09/21/2004US6794151 c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
09/21/2004US6794137 Detecting exposure of a cell to ultraviolet radiation; obtain cells, screen for preferential gene expression, monitor cells for adjusted tubulin protein expression
09/21/2004US6793924 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated t cells and thereby inhibits t cell activation of b cells
09/21/2004CA2458085A1 Transcriptional activity assay
09/21/2004CA2155843C Novel urea derivatives, their preparation and use
09/16/2004WO2004078987A1 A recombinant constructed by a virus vector and a human tumor suppressor gene and its use
09/16/2004WO2004078970A1 Branched neutral amino acid transporters acting as single molecule
09/16/2004WO2004078781A1 Protein-binding doxorubicin peptide derivatives
09/16/2004WO2004078770A1 Bifunctional heterocyclic compounds and methods of making and using the same
09/16/2004WO2004078764A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
09/16/2004WO2004078758A1 Novel fused heterocycles and uses thereof
09/16/2004WO2004078748A2 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
09/16/2004WO2004078747A1 Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
09/16/2004WO2004078746A2 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
09/16/2004WO2004078723A1 Novel compound having 4-pyridylalkylthio group as substituent
09/16/2004WO2004078695A1 Method for the purification of crocetin
09/16/2004WO2004078677A2 Enhanced delivery of sphingolipids
09/16/2004WO2004078206A1 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
09/16/2004WO2004078205A1 Targeting a protein prc1 for the treatment of pancreatic cancer
09/16/2004WO2004078202A1 Clostridial neurotoxins for treating uterine disorders
09/16/2004WO2004078191A1 Composition for treating hepatitis c
09/16/2004WO2004078184A1 Use of adenosine receptor agonists in therapy
09/16/2004WO2004078140A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
09/16/2004WO2004078137A2 Antitumor agents comprising a targeting portion and an immune response triggering portion
09/16/2004WO2004078133A2 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
09/16/2004WO2004078128A2 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
09/16/2004WO2004078123A2 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
09/16/2004WO2004078110A2 Fused imizadoles as transforming growth factor (tgf) inhibitors
09/16/2004WO2004078097A2 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
09/16/2004WO2004063711A3 Use of adiponectin to diagnose and treat malignancy
09/16/2004WO2004062592A3 2-o sulfatase compositions and related methods
09/16/2004WO2004055513A3 Use of cd137 antagonists for the treatment of tumors
09/16/2004WO2004050096A3 Phosphoantigens for regulating an immune response
09/16/2004WO2004048409A3 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids
09/16/2004WO2004046188A3 Anti-activated ras antibodies
09/16/2004WO2004046101A3 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
09/16/2004WO2004043389B1 Methods of treating cancer and related methods
09/16/2004WO2004013180A3 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
09/16/2004WO2004005540A3 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
09/16/2004WO2004004632A3 Flavone derivatives as inhibitors of cyclin-dependent kinases
09/16/2004WO2003088898A3 Compositions and methods for the diagnosis and treatment of tumor
09/16/2004WO2003083041A8 Cripto-specific antibodies
09/16/2004WO2003073989A3 Nucleoside 5'-monophosphate mimics and their prodrugs
09/16/2004WO2003065971A3 Non-myeloablative tolerogenic treatment with tyrphostins
09/16/2004WO2003053457A8 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
09/16/2004WO2003052048A3 Nucleic acid-associated proteins
09/16/2004WO2003045318A3 Manipulation of cytokine levels using cd83 gene products
09/16/2004WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies
09/16/2004WO2002099043A8 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
09/16/2004US20040181076 Reaction of carbazolone, forrmaldehyde and amine compound in nonaqueous solution and bonding to water, solvent
09/16/2004US20040181066 Tyrosine kinase inhibitors
09/16/2004US20040181062 Benzimidazole cyclooxygenase-2 inhibitor
09/16/2004US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
09/16/2004US20040181047 33 human secreted proteins
09/16/2004US20040181041 Fusion protein capable of inducing programmed cell death for use in treatment cell proliferative diseases and infection
09/16/2004US20040181037 Phosphatidyl serine receptors and uses thereof
09/16/2004US20040181036 Mutant forms of cholera holotoxin as an adjuvant
09/16/2004US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder
09/16/2004US20040180962 Dosage forms having prolonged active ingredient release
09/16/2004US20040180956 calcium salt is calcium trifluoroacetate; to prepare medicaments with cytotoxic and antitumoral activity
09/16/2004US20040180955 to establish a low circulating concentration of suramin in the patient of below about 200 mu, then administering cytotoxic agent
09/16/2004US20040180949 conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue
09/16/2004US20040180944 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction
09/16/2004US20040180938 More preferred compound is (1Z,3E)-1-methyl-1-(4-carboxyphenyl)-2-methoxycarbonyl-3-(2-methylpyridin-4-yl)aminocarbonyl-4-(3-methoxyphenyl)butadiene; for the treatment of acute coronary symptoms
09/16/2004US20040180929 Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents
09/16/2004US20040180917 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same
09/16/2004US20040180914 5-Cyano-2-aminopyrimidine derivatives
09/16/2004US20040180911 for the treatment of a proliferative disease, such as a tumor
09/16/2004US20040180901 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
09/16/2004US20040180899 tyrosine kinase inhibitors
09/16/2004US20040180891 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
09/16/2004US20040180890 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
09/16/2004US20040180889 Cancer treatment; such as [4-(2,5-dimethyl-pyrrol-1-yl)-3-methyl-phenoxy]-acetic acid
09/16/2004US20040180887 N-aroyl cyclic amine derivatives as orexin receptor antagonists
09/16/2004US20040180881 Oxazolyl-pyrazole derivatives as kinase inhibitors
09/16/2004US20040180878 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
09/16/2004US20040180858 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate